Cleared Traditional

K960871 - SPECTROLYSE ANTITHROMBIN III (ANTI-XA)

K960871 is an FDA 510(k) clearance for SPECTROLYSE ANTITHROMBIN III (ANTI-XA), manufactured by Medical Diagnostic Technologies, Inc.. The device is a Class 2 Hematology device with product code JBQ cleared through the Traditional 510(k) pathway after a 163-day FDA review.

K960871 · Medical Diagnostic Technologies, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1996
Decision
163d
Days
Class 2
Risk

K960871 is an FDA 510(k) clearance for the SPECTROLYSE ANTITHROMBIN III (ANTI-XA). Classified as Antithrombin Iii Quantitation (product code JBQ), Class II - Special Controls.

Submitted by Medical Diagnostic Technologies, Inc. (Ventura, US). The FDA issued a Cleared decision on August 14, 1996 after a review of 163 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7060 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Medical Diagnostic Technologies, Inc. devices

FDA 510(k) Submission Details - K960871

510(k) Number K960871 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 04, 1996
Decision Date August 14, 1996
Days to Decision 163 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
50d slower than avg
Panel avg: 113d · This submission: 163d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

JBQ Device Classification - Class 2, Special Controls

Product Code JBQ Antithrombin Iii Quantitation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7060
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - JBQ Antithrombin Iii Quantitation

All 47
Devices cleared under the same product code (JBQ) and FDA review panel - the closest regulatory comparables to K960871.
IL TEST ANTITHROMBIN
K980499 · Instrumentation Laboratory CO · Apr 1998
IMMAGE IMMUNOCHEMISTRY SYSTEM ANTITHROMBIN III (AT3) REAGENT
K974110 · Beckman Instruments, Inc. · Dec 1997
SIGMA DIAGNOSTICS ACCUCOLOR ANTITHROMBIN III
K972144 · Sigma Diagnostics, Inc. · Jul 1997
COACUTE ANTITHROMBIN R CHROMOGENIC ASSAY
K952515 · Chromogenix AB · Jan 1996
CHROM Z CHROMOGENIC ASSAYS
K951943 · Helena Laboratories · Nov 1995
AT-III CALIBRATOR
K944279 · American Bioproducts Co. · Apr 1995